scispace - formally typeset
T

Thomas A. Rawlinson

Researcher at University of Oxford

Publications -  19
Citations -  2147

Thomas A. Rawlinson is an academic researcher from University of Oxford. The author has contributed to research in topics: Plasmodium vivax & Malaria. The author has an hindex of 8, co-authored 16 publications receiving 1107 citations.

Papers
More filters
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Journal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
TL;DR: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
Journal ArticleDOI

Rapid and iterative genome editing in the malaria parasite Plasmodium knowlesi provides new tools for P. vivax research

TL;DR: CRISPR-Cas9 genome editing is established in a culture-adapted P. knowlesi strain and parameters for optimal homology-driven repair are defined, establishing a scalable protocol for the production of repair templates by PCR and demonstrating the flexibility of the system by tagging proteins with distinct cellular localisations.
Journal ArticleDOI

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.

TL;DR: It is shown that growth inhibition activity measured in vitro using purified immunoglobulin G (IgG) antibody strongly correlates with in vivo reduction of the parasite growth rate and also identify other antibody feature sets by systems serology, including the plasma anti-RH5 IgA1 response, that are associated with challenge outcome.